How viruses can help fight antibiotic-resistant infections
So-called phage therapy could be the next big thing
First, the bad news: Thanks to repeated drug exposure, climate change and air pollution, some infections are developing resistance to antibiotics, a problem that could have global repercussions as diseases become stronger and more prevalent. The good news? Scientists are currently considering an unexpected solution.
Researchers are looking to bacteriophages, or viruses that specifically target bacteria, to help cure infections. "Phages are the most abundant biological form on the planet," microbiologist Bryan Gibb, an associate professor of biological and chemical sciences, told News Medical. "These naturally occurring viruses are professional bacterial assassins." Experts in the medical field have become more invested in so-called phage therapy as antibiotics meanwhile become less effective.
Phage therapy is currently considered experimental in the U.S. and “can only be used in emergency or compassionate use cases when few or no other treatments are available," Popular Science wrote. It can be administered "intravenously, orally, topically, or intranasally." Though it's considered safe, the efficacy of the treatment has received "mixed reviews." However, "this may reflect a poor match between the selected phage and the bacteria it was meant to target." With more research, phage therapy could become more widespread and potentially cheaper than antibiotics. "One of the biggest hurdles to making this treatment mainstream, aside from regulation, is a lack of awareness around phage therapy's life-saving potential," Maclean's Greg German explained. “Antimicrobial resistance is a battle that can't be won on one front. It's going to take every weapon we've got."
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Devika Rao has worked as a staff writer at The Week since 2022, covering science, the environment, climate and business. She previously worked as a policy associate for a nonprofit organization advocating for environmental action from a business perspective.
-
The six-seven meme that has taken over the worldIn the Spotlight With roots in rap and basketball, the phrase has young people obsessed, and it could be here to stay
-
Five takeaways from Plaid Cymru’s historic Caerphilly by-election winThe Explainer The ‘big beasts’ were ‘humbled’ but there was disappointment for second-placed Reform too
-
A journey through Trinidad’s wild heartThe Week Recommends Experience the island’s natural wonders, from watching baby turtles hatch to visiting an ancient bat cave
-
Doctors sound the alarm about insurance company ‘downcoding’The Explainer ‘It’s blatantly disrespectful,’ one doctor said
-
Climate change is getting under our skinUnder the radar Skin conditions are worsening because of warming temperatures
-
Bluetoothing: the phenomenon driving HIV spike in FijiUnder the Radar ‘Blood-swapping’ between drug users fuelling growing health crisis on Pacific island
-
FDA OKs generic abortion pill, riling the rightSpeed Read The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
-
‘Nightmare bacteria’ are rapidly spreadingUnder the radar The infections are largely resistant to antibiotics
-
Kissing bug disease has a growing presence in the USThe explainer The disease has yielded a steady stream of cases in the last 10 years
-
Private equity firms might be causing more deaths in hospital ERsThe Explainer Deaths in ERs purchased by private equity firms rose 13%
-
RFK Jr. vaccine panel advises restricting MMRV shotSpeed Read The committee voted to restrict access to a childhood vaccine against chickenpox
